In 2020, the results of the IMspire150 trial showed that adding atezolizumab to BRAFi/MEKi in patients with BRAF(V600)-mutated advanced melanoma resulted in improved PFS with acceptable tolerance (59). This evidence concerns the gene BRAF and melanoma.